ResMed Rises to 432nd in Market Activity Amid 13.1% Earnings Growth Outlook and $0.24 Billion Volume

On August 11, 2025, ResMed (RMD) closed up 0.15%, with a trading volume of $0.24 billion, ranking 432nd in market activity. The stock’s performance reflects ongoing interest in its growth potential and strategic positioning in the respiratory care sector.

ResMed holds a Zacks Rank of #3 (Hold) and a VGM Score of A, indicating a balanced mix of value, growth, and momentum characteristics. Its Growth Style Score of A highlights strong earnings projections, including a 13.1% year-over-year earnings growth forecast for fiscal 2025. Analysts revised earnings estimates upward by $0.37 per share in the past 60 days, raising the Zacks Consensus Estimate to $10.80. This aligns with the company’s historical average earnings surprise of +4.5%, underscoring confidence in its ability to exceed expectations.

Recent data shows ResMed’s dominance in sleep-disordered breathing treatments and cloud-based respiratory solutions. The company’s focus on innovation, including its AirView remote monitoring platform and myAir app, drives patient adherence and therapeutic outcomes. However, macroeconomic pressures and pricing challenges in key markets remain risks to margin stability.

A backtested strategy of purchasing the top 500 stocks by daily trading volume and holding for one day returned 166.71% from 2022 to the present, outperforming the benchmark’s 29.18% by 137.53%. This underscores the role of liquidity concentration in short-term gains, particularly in volatile markets where high-volume stocks react swiftly to market dynamics.